Loading organizations...
§ Private Profile · Seattle, WA, USA
Parse Biosciences is a technology company.
Parse Biosciences develops scalable single-cell sequencing solutions, centered around its Evercode™ technology platform. This system offers an end-to-end workflow, encompassing reagent kits for library preparation and intuitive analysis software called Trailmaker, allowing researchers to perform experiments across various scales without the limitations inherent in microfluidics-based approaches. The company’s products facilitate comprehensive cellular analysis, transforming complex biological inquiries into actionable insights.
The company was founded in 2018 by Alex Rosenberg, PhD, and Charles Roco, PhD. Both co-founders emerged from the University of Washington, where Rosenberg was a postdoctoral fellow. Their founding insight stemmed from a recognition of existing bottlenecks in single-cell sequencing, leading them to pursue a more accessible and scalable methodology to accelerate biological discovery.
Parse Biosciences' technology is adopted by researchers in both academic and pharmaceutical settings, enabling deeper understanding of biological systems at a cellular level. The company’s vision is to propel single-cell science forward through continuous innovation, empowering the scientific community with novel capabilities to advance human health and scientific research. They strive to make sophisticated single-cell analysis broadly available and impactful.
Parse Biosciences has raised $99.0M across 3 funding rounds.
Parse Biosciences has raised $99.0M in total across 3 funding rounds.
Parse Biosciences has raised $99.0M in total across 3 funding rounds.
Parse Biosciences's investors include David Canner, Bioeconomy Capital, Janus Henderson Investors, Marshall Wace, Sahsen Ventures, Saras Capital, Logos Capital, Soleus Capital.
Parse Biosciences has raised $99.0M across 3 funding rounds. Most recently, it raised $50.0M Series C in December 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 14, 2023 | $50M Series C | David Canner | Bioeconomy Capital, Janus Henderson Investors, Marshall Wace, Sahsen Ventures, Saras Capital | Announced |
| Feb 1, 2022 | $42M Series B | Janus Henderson Investors, Marshall Wace | Bioeconomy Capital, Logos Capital, Soleus Capital | Announced |
| Jan 1, 2021 | $7M Series A | Bioeconomy Capital | — | Announced |
Parse Biosciences is a Seattle-based biotechnology company founded in 2018 that develops scalable single-cell sequencing platforms for researchers.[1][2][6] Its core product, the Evercode™ technology, uses combinatorial barcoding to enable high-throughput single-cell RNA sequencing without specialized instruments, serving academic labs, biotech firms, and pharmaceutical researchers studying complex biology like cancer, immunotherapy, and stem cell therapy.[2][4] This solves key pain points in traditional microfluidics-based methods, such as limited scale, high costs, and equipment dependency, allowing unprecedented experiment sizes—over 3,000 labs worldwide have processed millions of cells with it.[1][4] The company has shown strong growth momentum, evolving from SPLiT Biosciences and driving innovations in areas like developmental biology and neurology.[2][6]
Parse Biosciences emerged from groundbreaking academic research in single-cell sequencing. The technology stems from SPLiT-seq, a split-pool combinatorial barcoding method published in *Science* in 2018, which inspired the company's founding that same year at the University of Washington ecosystem via CoMotion.[1][6] Originally named SPLiT Biosciences, it rebranded to Parse Biosciences to reflect its focus on scalable tools.[6] Founders drew from expertise in genomics and biotech, aiming to democratize single-cell analysis amid rising demand for insights into diseases like COVID-19 and cancer.[2] Early traction came from proving the tech's ability to handle massive cell counts without custom hardware, quickly attracting researchers and fueling rapid innovation.[1][4]
Parse stands out in single-cell sequencing through these key advantages:
Parse rides the explosive growth of single-cell genomics, a trend transforming biology by revealing cellular heterogeneity critical for precision medicine, drug discovery, and understanding diseases like cancer and neurodegeneration.[1][2] Timing is ideal: post-2018 SPLiT-seq publication aligned with surging demand from COVID-19 research and advances in immunotherapy, where single-cell data unlocks hidden biology.[2] Market tailwinds include falling sequencing costs, AI-driven analysis, and biotech's push for scalable tools—Parse influences the ecosystem by lowering barriers, enabling smaller labs to compete, and fostering breakthroughs in stem cell therapy and vascular disease.[2][4] As a private player (no IPO yet), it complements giants like 10x Genomics while carving a niche in high-scale, accessible tech.[3][5]
Parse is poised to dominate scalable single-cell sequencing as labs demand ever-larger datasets for AI-powered biology. Next steps likely include expanding Evercode kits, deeper software integrations, and potential funding or IPO amid biotech's recovery—watch for partnerships in drug development.[3][4][5] Trends like multi-omics and fixed-sample workflows will propel it, evolving its role from enabler to ecosystem leader in human health discoveries. This Seattle innovator, born from SPLiT-seq's spark, continues scaling science without limits.[1][2]